Valiant Co

Valiant Co Financing Cash Flow

The Net Financing Cash Flow of Valiant Co (002643.SZ) as of Nov 19, 2026 is -15.22 M CNY. In the previous year, Net Financing Cash Flow was 349.92 M CNY — a change of -104.35% (lower).

Financing Cash Flow

-15.22 MCNY

YoY

-104.35%

Last updated:

Net Financing Cash Flow of Valiant Co is 2024 -15.22 M CNY. Net Financing Cash Flow of Valiant Co was 2023 349.92 M CNY. It decreases by -104.35% lower compared to the previous year.

The Valiant Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
-130.01 M CNY
Jan 1, 2018
28.00 M CNY
Jan 1, 2019
27.45 M CNY
Jan 1, 2020
289.82 M CNY
Jan 1, 2021
3.13 M CNY
Jan 1, 2022
70.34 M CNY
Jan 1, 2023
349.92 M CNY
Jan 1, 2024
-15.22 M CNY
The Valiant Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
-15.22 MCNY-104.35%
349.92 MCNY+397.48%
70.34 MCNY+2,146.36%
3.13 MCNY-98.92%
289.82 MCNY+956.02%
27.45 MCNY-1.98%
28.00 MCNY-121.53%
-130.01 MCNY-114.94%
870.11 MCNY-5.99%
925.53 MCNY-2,104.84%
-46.16 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Co Stock analysis

What does Valiant Co do? Valiant Co., Ltd. generates revenue through three core business segments. The Information Materials Industry segment produces and sells display materials and functional materials, targeting customers in the electronics and manufacturing sectors. The Environmental Protection Materials Industry segment develops and manufactures new zeolite environmental protection materials for tail gas purification, serving automotive and industrial clients requiring emission control solutions. The Large Health Industry segment focuses on pharmaceutical production, life sciences, and in vitro diagnostic services, catering to healthcare providers and medical facilities. The company's products include display materials, functional materials, new zeolite environmental protection materials, pharmaceuticals, and in vitro diagnostic services. These offerings are sold across the three industry segments, with the Environmental Protection Materials segment specifically addressing tail gas purification needs. The Large Health Industry segment's in vitro diagnostic services support healthcare operations through specialized medical solutions. Valiant Co., Ltd. serves diverse customer segments including electronics manufacturers, automotive industries, industrial emission control clients, and healthcare providers. The firm's revenue streams are derived from the sale of physical products like display materials and zeolite materials, as well as service-based offerings in diagnostics and pharmaceuticals. The company's business model relies on manufacturing and selling these products across its three operational segments. Valiant Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Co stock

Net Financing Cash Flow of Valiant Co is -15.22 M CNY in 2024.

Net Financing Cash Flow of Valiant Co changed from 349.92 M CNY to -15.22 M CNY, representing a -104.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Valiant Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Valiant Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Valiant Co

All Key Metrics — Valiant Co